Twist Bioscience (TWST) reported a fiscal Q4 loss Monday of $0.59 per diluted share, narrower than its loss of $0.81 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.70.
Revenue for the quarter ended Sept. 30 was $84.7 million, up from $66.9 million a year earlier.
Analysts surveyed by Capital IQ expected $82.7 million.
The company said it expects fiscal Q1 revenue of approximately $87 million. Analysts surveyed by Capital IQ expect $84.3 million.
For fiscal year 2025, the company expects revenue in a range between $367 million and $377 million. Analysts polled by Capital IQ expect $373.2 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.